Prestige BioPharma Limited

Singapore biopharmaceutical company founded in 2015, dedicated to biosimilar development and new antibody therapies. Pipeline of over 12 biosimilars includes: HD201 (trastuzumab), HD204 (bevacizumab) and PBP1502 (adalimumab). Also developing PBP1510 (Ulenistamab), first-in-class antibody for pancreatic cancer in Phase 1/2a. 201-500 employees.